These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1588053)

  • 1. H-2K double transfectants of tumor cells as antimetastatic cellular vaccines in heterozygous recipients. Implications for the T cell repertoire.
    Mandelboim O; Feldman M; Eisenbach L
    J Immunol; 1992 Jun; 148(11):3666-73. PubMed ID: 1588053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells.
    Mandelboim O; Vadai E; Feldman M; Eisenbach L
    Gene Ther; 1995 Dec; 2(10):757-65. PubMed ID: 8750016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abolishment of metastasis formation by murine tumor cells transfected with "foreign" H-2K genes.
    Gelber C; Plaksin D; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1989 May; 49(9):2366-73. PubMed ID: 2784997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.
    Porgador A; Tzehoval E; Katz A; Vadai E; Revel M; Feldman M; Eisenbach L
    Cancer Res; 1992 Jul; 52(13):3679-86. PubMed ID: 1617640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association in the expression of Kirsten-ras oncogene and the major histocompatibility complex class I antigens in fibrosarcoma tumor cell variants exhibiting different metastatic capabilities.
    Alon Y; Hammerling GJ; Segal S; Bar-Eli M
    Cancer Res; 1987 May; 47(10):2553-7. PubMed ID: 3552201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of F1 cytotoxic potentials by graft-vs-host reaction. Cooperative non-H-2- and H-2D region-gene control of F1 natural resistance to graft-vs-host reaction-associated immunosuppression.
    Ishikawa H; Saito K; Kubota E
    J Immunol; 1989 Mar; 142(5):1495-9. PubMed ID: 2918225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-fos and c-jun overexpression in malignant cells reduces their tumorigenic and metastatic potential, and affects their MHC class I gene expression.
    Yamit-Hezi A; Plaksin D; Eisenbach L
    Oncogene; 1994 Apr; 9(4):1065-79. PubMed ID: 8134110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells.
    Porgador A; Bannerji R; Watanabe Y; Feldman M; Gilboa E; Eisenbach L
    J Immunol; 1993 Feb; 150(4):1458-70. PubMed ID: 8432988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma.
    Nishimura MI; Stroynowski I; Hood L; Ostrand-Rosenberg S
    J Immunol; 1988 Dec; 141(12):4403-9. PubMed ID: 3264312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class I genes controlling the metastatic phenotype of tumor cells.
    Feldman M; Eisenbach L
    Semin Cancer Biol; 1991 Oct; 2(5):337-46. PubMed ID: 1773049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to NK and metastatic potential of fibrosarcoma cells is associated with products encoded by the H-2D region.
    Rager-Zisman B; Aboud M; Gopas J; Har-Vardi I; Hämmerling GJ; Segal S
    Semin Cancer Biol; 1991 Oct; 2(5):329-36. PubMed ID: 1773048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T lymphocyte response to minor H-43a alloantigen in H-43b mice. Privileged H-2Kb restriction to the response is not due to immunodominance or epistatic effect but due to Ir gene function of H-2Kb itself.
    Hino T; Ishikawa H; Saito K
    J Immunol; 1988 Jan; 140(1):44-51. PubMed ID: 3121741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic control of the induction of cytolytic T lymphocyte responses to AKR/Gross viral leukemias. I. H-2-encoded dominant gene control.
    Green WR
    J Immunol; 1984 May; 132(5):2658-64. PubMed ID: 6425409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic T lymphocyte response to minor H-42a alloantigen in H-42b mice: clonal inactivation of the precursor cytotoxic T lymphocytes by veto-like spleen cells that express the H-42a antigen.
    Ishikawa H; Hino T; Kato H; Suzuki H; Saito K
    J Immunol; 1986 Oct; 137(7):2080-8. PubMed ID: 3489752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic capacity of cloned T10 sarcoma cells that differ in H-2 expression: inverse relationship to their immunogenic potency.
    Katzav S; Segal S; Feldman M
    J Natl Cancer Inst; 1985 Aug; 75(2):307-18. PubMed ID: 3894752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene.
    Hui KM; Sim T; Foo TT; Oei AA
    J Immunol; 1989 Dec; 143(11):3835-43. PubMed ID: 2584720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The target minor H antigen for F1 cytotoxic T lymphocytes induced by Igh-congenic parental spleen cells is coded for by gene linked to H-2.
    Ishikawa H; Kubota E; Suzuki H; Saito K
    J Immunol; 1985 May; 134(5):2953-9. PubMed ID: 2580009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
    Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
    Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
    Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T
    J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.